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Edited by Vladimir SkulachevAbstract The protective eﬀects of huperzine A against oxygen–
glucose deprivation (OGD)-induced injury in C6 cells were inves-
tigated. OGD for 6 h and reoxygenation for 6 h enhanced
phosphorylation and degradation of IjBa and nuclear transloca-
tion of nuclear factor-kappa B (NF-jB), triggered overexpression
of inducible nitric oxide synthase (iNOS), cyclooxygenase-2
(COX-2) and nitric oxide (NO) in C6 cells. Along with inhibiting
acetylcholinesterase activity, treatment with 1 lM huperzine A
inhibited activation of NF-jB, attenuated iNOS, COX-2 and
NO overexpression, and promoted survival in C6 cells subjected
to OGD insult. The protective eﬀects of huperzine A were partly
mediated by ‘‘cholinergic anti-inﬂammatory pathway’’ through
a7 nicotinic acetylcholine receptor.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Based on the ‘‘cholinergic hypothesis’’, acetylcholinesterase
(AChE) inhibitors have been developed as promising agents
for palliative therapy of Alzheimer’s disease (AD) [1]. Studies
on pathogenic mechanisms have revealed that patients with
vascular dementia (VaD) exhibit cholinergic abnormalities
and disturbance of cognitive function similar to those in AD
[2]. These ﬁndings raise the possibility of using AChE inhibitors
to alleviate ischemic brain injury. Several studies show that
many AChE inhibitors have neuroprotective eﬀects against
ischemia-induced injury in vitro and in vivo [3–5]. Furthermore,
three AChE inhibitors approved for use in AD, i.e. donepezil,
rivastigmine, and galantamine, have been used in VaD [6].Abbreviations: AD, Alzheimer’s disease; VaD, vascular dementia;
OGD, oxygen–glucose deprivation; iNOS, inducible nitric oxide syn-
thase; COX-2, cyclooxygenase-2; NO, nitric oxide; NF-jB, transcrip-
tion factor nuclear factor-kappa B; PDTC, pyrrolidinedithiocarbamate;
AChE, acetylcholinesterase; nAChR, nicotinic acetylcholine receptor;
ROS, reactive oxygen species; ACh, acetylcholine; DMEM, Dulbecco’s
modiﬁed Eagle’s medium; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphe-
nyltetrazolium bromide; EBSS, Earle’s balanced salt solution; DAPI,
4,6-diamidino-2-phenylindole
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doi:10.1016/j.febslet.2007.01.016Huperzine A, an alkaloid isolated from the Chinese folk
medicine Huperzia serrata, is a reversible and selective inhibi-
tor of AChE that has been used to treat AD in China [7–9].
Several clinical trials have addressed the eﬀects of huperzine
A on VaD [9]. Our previous studies show that, besides inhibit-
ing AChE, huperzine A has a range of neuroprotective activi-
ties against neurotoxicity induced by glutamate, hydrogen
peroxide, b-amyloid peptide fragments 25–35 and stauro-
sporine [9]. We also demonstrate the neuroprotective eﬀects
of huperzine A on several ischemic models in vitro and
in vivo [8,10]. It has been shown that the ability of huperzine
A against ischemia is due to its actions, not only on the cholin-
ergic system, but also on the oxygen free radical system, energy
metabolism, apoptosis and neurotrophic factors [9].
Inﬂammatory reaction is involved in cerebral ischemia [11].
It is a consequence of activation of glial cells and resident mac-
rophages and inﬁltration of peripheral inﬂammatory cells into
the brain [12,13]. Inﬂammation contributes to the late stages of
ischemic injury, alleviates neuronal survival and results in
worsening of neurologic outcome. Recent researches show that
some AChE inhibitors suppress several inﬂammatory reactions
such as T-cell proliferation, cytokine production and CNS
inﬂammation, concomitantly with inhibiting AChE activity,
which suggest a novel therapeutic mechanism for AChE inhib-
itors [14–16]. It is therefore worth ﬁnding out whether huper-
zine A has similar anti-inﬂammatory properties. We have
now tested the anti-inﬂammatory eﬀects of huperzine A in
an in vitro model of ischemia based on oxygen–glucose depri-
vation (OGD) in C6 rat glioma cell, which is well known to be
a useful model system for the study of inﬂammation in the glial
cells [17–19].2. Materials and methods
2.1. Cell culture and OGD treatment
C6 cells were purchased from the American Type Culture Collection
and maintained at 37 C in a humidiﬁed atmosphere containing 5%
CO2. Cells were seeded in Dulbecco’s modiﬁed Eagle’s medium
(DMEM), supplemented with 10% fetal bovine serum. Experiments
were carried out 24 h after cells were seeded. For OGD insult, the ori-
ginal media were removed and the cells were washed with oxygen and
glucose-free Earle’s balanced salt solution (EBSS, pH 7.4). The cul-
tures were then placed in fresh oxygen and glucose-free EBSS and held
in an incubator containing 95% (v/v) N2 and 5% (v/v) CO2 at 37 C for
6 h. At the end of exposure period, glucose was added, and the cells
were returned to normal condition for an additional 6 h. Huperzine
A (colorless powder, purity >99%, provided by the Department of
Phytochemistry in this Institute) was dissolved and diluted in phos-
phate-buﬀered saline (PBS). According to our previous studies, 1 lMblished by Elsevier B.V. All rights reserved.
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fore, huperzine A was added into the cultures 2 h before OGD treat-
ment at concentration of 1 lM. Control cultures were placed in
EBSS with glucose and maintained for the same time interval in the
incubator under normal condition.
2.2. Cell survival determination
Cell survival was evaluated by the ability to reduce 3-[4,5-dimethyl-
thiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Sigma), an indi-
cation of metabolic activity. MTT stock solution in PBS was added per
well with a ﬁnal concentration of 0.5 mg/ml, and the incubation was
continued for another 4 h at 37 C. Finally, an equal volume of a solu-
tion containing 50% dimethylformamide and 20% sodium dodecyl sul-
fate (SDS, pH 4.8) was added. The mixtures were kept overnight at
room temperature, and then the amount of MTT formazan was quan-
tiﬁed by determining the absorbance at 570 nm and 630 nm using a
Universal Microplate Reader (Bio-Tek).
2.3. Measurement of nitric oxide (NO) by nitrite assay
NO production was determined by measurement of nitrite ðNO2 Þ, a
stable oxidative product of NO. The nitrite level in cell-free superna-
tant was determined by using Griess reagent. In brief, 100 ll of culture
medium was mixed with 100 ll of Griess reagent and incubated in a 96-
well plate for 15 min at room temperature. Absorbance at 570 nm was
determined by using a Universal Microplate Reader (Bio-Tek) with
reference to NaNO2 as standard.
2.4. Western blot analysis
Cells were harvested, lysed and then centrifuged at 10000 · g for
10 min at 4 C. Supernatant solutions were collected. Protein concen-
trations were determined by Coomassie blue protein binding method
using bovine serum albumin as standard. Samples containing equal
amounts of protein (50 lg) were boiled in protein loading buﬀer for
10 min, separated on 10% SDS–polyacrylamide gels and transferred
to nitrocellulose membranes. After blocking with TBST (Tris-buﬀered
saline with 0.1% Tween) containing 5% non-fat milk, the membranes
were kept at 4 C overnight with primary antibodies, followed by
HRP-conjugated second antibodies at room temperature for 2 h. The
target protein bands were detected using the ECL plus Western blot-
ting detection system (Amersham Biosciences) and Kodak X-ray ﬁlm.
2.5. Immunostaining
Nuclear translocation of p65: Cultures were ﬁxed with 4% parafor-
maldehyde at 4 C for 30 min, rinsed with PBST (PBS with 0.2% Tri-
ton X-100) and blocked with 10% goat serum in PBST for 2 h at room
temperature. Cells were then reacted with rabbit anti-p65 (Chemicon)
at 37 C for 2 h, followed by Cy3-conjugated goat anti-rabbit second-
ary antibody (Sigma). After washed with PBST, cells were incubated in
1 mg/L 4,6-diamidino-2-phenylindole (DAPI) (ICN Biomedicals) solu-
tion for 15 min in the dark and then examined under a Nikon ﬂuores-
cent microscope.
FITC-labelled a-bungarotoxin binding assay: Cells were incubated
at 37 C for 30 min with FITC-labelled a-bungarotoxin (Sigma) at
1.5 lg/ml. Where indicated, nicotine (Sigma) was added at the concen-
tration of 500 lM for 15 min, in order to saturate all the binding sites
before the addition of FITC-labelled a-bungarotoxin. Cells were
washed three times with DMEMmedium and then ﬁxed with 4% para-
formaldehyde at room temperature for 15 min. After ﬁxation, cells
were washed twice with PBS solution, mounted in PBS:glycerol and
examined using a Nikon ﬂuorescent microscope.2.6. RT-PCR
Total RNA was isolated using TRIzol reagent (Invitrogen) and re-
verse-transcribed into cDNA using Reverse Transcription System
(Promega). The cDNA solutions were ampliﬁed with the following spe-
ciﬁc primers based on the rat AChE and a7 nicotinic acetylcholine
receptor (nAChR) sequences. AChE: 5 0-TCTTTGCTCAGCGACT-
TA-30 (upstream), 50-GTCACAGGTCTGAGCATCT-30 (downstream);
a7 nAChR: 50-TCAACAGAAACGTGACAAGGCCG-30 (upstream),
50-GGCCAGCGCCATCTTGTAATGG-30 (downstream). Ampliﬁca-
tions were performed as follows: AChE: 40 cycles, 94 C for 45 s,
56 C for 45 s, 72 C for 45 s; a7 nAChR: 30 cycles of 95 C for 60 s,
64 C for 60 s and 72 C for 60 s. PCR products were separated by1.5% agarose gels containing 0.5 lg/ml ethidium bromide and photo-
graphed by an ultraviolet gel documentation system.
2.7. AChE activity assay
Cells were harvested, lysed and then centrifuged at 10000 · g for
10 min at 4 C. Supernatant solutions were used to determine AChE
activity by the Ellman spectrophotometric method [20]. Protein con-
centrations were determined by Coomassie blue protein binding meth-
od using bovine serum albumin as standard.
2.8. Measurement of acetylcholine (ACh)
ACh concentrations in extracts of C6 cells were determined with an
HPLC-ECD system (ESA Bedford, MA, USA) at a potential of
200 mV versus Pd reference electrode. The mobile phase contained
100 mM Na2HPO4, 0.5 mM tetramethylammonium chloride, 2 mM
octane sulfonic acid and 0.005% Reagent MB (ESA Bedford) at pH
8.0. Flow rate was set at 0.5 ml/min. The peaks were displayed, inte-
grated and stored by means of an EZChrom Elite data system (ESA
Bedford). The detection limit for ACh was 10 fmol per 10-ll injection.
2.9. Pharmacological inhibition
Two hours prior to OGD injury, pyrrolidinedithiocarbamate
(PDTC, 0.1 and 1 lM, Sigma) were added to the cultures. In other
experiments mecamylamine (1 lM, Sigma) or a-bungarotoxin
(10 nM, Sigma) was added for 30 min followed by 1 lM huperzine
A. After OGD for 6 h and reoxygenation for 6 h, cell viabilities and
NO contents in the culture medium were detected by MTT assay
and Griess reagent, respectively.
2.10. Statistical analysis
Data were expressed as means ± S.E.M. Statistical analysis was per-
formed by one-way analysis of variance (ANOVA) followed by Dun-
can’s multiple-range test, with P < 0.05 as the signiﬁcant level.3. Results
As determined by MTT reduction, C6 cells were very sensi-
tive to OGD insult. OGD for 6 h and reoxygenation for 6 h in-
duced death in nearly 35% of cells (Fig. 1A). We detected the
eﬀects of huperzine A on the protein levels of two proinﬂam-
matory enzymes, inducible nitric oxide synthase (iNOS) and
cyclooxygenase-2 (COX-2), in OGD-treated C6 cells by Wes-
tern blot analysis. After OGD treatment, both iNOS and
COX-2 protein levels were moderately increased (Fig. 1B,
C). In addition, NO content in culture medium of cells rose
nearly 300% after OGD injury (Fig. 1D). Huperzine A at
1 lM markedly increased cell survival, suppressed the induc-
tion of iNOS and COX-2 protein expression and attenuated
overproduction of NO. In contrast, huperzine A had no eﬀect
on the viability, protein expression of these enzymes and NO
production in cells maintained under normal condition.
Because increased iNOS and COX-2 expression during
inﬂammatory, hypoxic or oxidative stress often involves activa-
tion of transcription factor nuclear factor-kappa B (NF-jB), we
sought to determine whether this signaling pathway was in-
volved in OGD-induced cell damage. For this purpose, we
added PDTC, a strong NF-jB inhibitor, to the cell culture 2 h
before OGD insult. As shown in Fig. 2, after OGD, pretreat-
ment with 0.1 and 1 lMPDTC increased the cell survival signif-
icantly and attenuated the overproduction of NO. In other C6
cultures maintained under normal condition, PDTC had no di-
rect eﬀect on cell viability or NO content in the medium.
In view of the indications for NF-jB-dependent signaling in
the protective eﬀects of huperzine A, we examined an early step
in this pathway, namely phosphorylation and degradation of
Fig. 1. Eﬀects of huperzine A on cell viability (A), iNOS and COX-2 protein expression (B, C) and NO production (D) in C6 cells. Concentration of
nitrite in the supernatants of control cells was 5.80 ± 1.17 lM. Data were means ± S.E.M. expressed as percentage of control value, which is set to
100%. At least three independent experiments were carried out in triplicate. **P < 0.01 versus control; ##P < 0.01 versus OGD group.
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lyze IjBa phosphorylation and accumulation in C6 cells sub-
jected to OGD insult in the absence or presence of 1 lM
huperzine A. The blots utilized an antibody that recognized
phosphorylated IjBa (Ser 32) and a phosphorylation-indepen-
dent antibody. As shown in Fig. 3A and B, OGD caused a
prominent increase of IjBa phosphorylation and a simulta-
neous loss of total IjBa protein. Huperzine A at 1 lM signi-
ﬁcantly inhibited the OGD-induced phosphorylation and
degradation of IjBa. However, 1 lM huperzine A did not af-
fect IjBa phosphorylation and degradation in untreated cells.
Since phosphorylation and digestion of IjBa usually induces
NF-jB translocation from cytoplasm to nucleus, we assessed
the localization of the NF-jB p65 subunit by immunostaining.
Resting C6 cells exhibited p65 immunoreactivity in cytoplasm
but little in the nucleus. Exposure to OGD insult caused a sub-
stantial shift of immunoreactivity to the nucleus. This translo-
cation was greatly inhibited by 1 lM huperzine A, which had
no eﬀect on p65 translocalization under normal condition
(Fig. 3C).
As detected by HPLC-ECD system, we found C6 cell con-
tained signiﬁcant amounts of ACh (164.96 ± 21.87 fmol/106
cells). AChE, the ACh hydrolyzing enzyme, is a principal tar-
get of huperzine A. Both RT-PCR and Western blot analysis
conﬁrmed the AChE expression in C6 cells with PC12 rat
pheochromocytoma cells known to express AChE as a positive
control (Fig. 4A, B). AChE activity dropped 20–25% after
OGD and reperfusion or treatment with 1 lM huperzine A,
and it dropped nearly 15% further after combined OGD with
huperzine A (Fig. 4C).We used mecamylamine, an antagonist against nAChR, to
determine whether nAChR was involved in the protective
eﬀects of huperzine A. Results of MTT reduction (Fig. 5A)
and NO content detection (Fig. 5B) showed that the protective
eﬀects of huperzine A were partly abolished in the presence of
1 lM mecamylamine. We conﬁrmed the expression of a7
nAChR in the C6 cells by RT-PCR, Western blot and immu-
noﬂuorescent assay (Fig. 5C, D). Furthermore, survival-sup-
porting and NO content-reducing activities of huperzine A
were partially attenuated in the presence of 10 nM a-bungaro-
toxin, a speciﬁc antagonist of a7 nAChR (Fig. 5E, F).4. Discussion
Our previous studies demonstrating anti-ischemic eﬀects of
huperzineA focused on neuronal cells [9]. Recent advances show
that glial cells also play signiﬁcant roles in the demise of brain
tissue after cerebral ischemia. In the present study, we demon-
strated the cytoprotective eﬀects of huperzine A in an in vitro
model of ischemia in C6 glioma cells, which is widely used in
studying inﬂammation andOGD [17–19]. In keeping with previ-
ous study [17], our present results showed a high sensitivity of
C6 cells to OGD insult, as determined by MTT reduction.
Abundant studies suggest important roles for glial cells in
ischemia-triggered inﬂammatory responses. The reaction of
glial cells to ischemia and other brain insults is similar in some
respects to the inﬂammatory response of peripheral tissues.
One of the important inﬂammatory mediators produced from
active glial cells is NO [21], which is a kind of free oxygen rad-
Fig. 2. Eﬀects of PDTC on cell viability (A) and NO production (B) in
C6 cells. Data were means ± S.E.M. expressed as percentage of control
value, which is set to 100%. At least three independent experiments
were carried out in triplicate. **P < 0.01 versus control; #P < 0.05,
##P < 0.01 versus OGD group.
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the late stage of cerebral ischemia, a persistent excess of NO,
generated by iNOS, is likely to be deleterious [23]. COX-2, an-
other inﬂammation-related enzyme, is upregulated with a time
course similar to that of iNOS, and in cells that are in close
proximity to each other [24]. COX-2 reaction products may
be another mechanism by which iNOS-derived NO contributes
to ischemic brain injury [25]. Compelling evidences have indi-
cated the roles of iNOS and COX-2 in OGD-induced cell death
[26,27]. Furthermore, iNOS or COX-2 inhibitors were also re-
ported to prevent cell death from OGD injury [28,29]. INOS
and COX-2 are therefore among the most promising pharma-
cological targets for the treatment of cerebral ischemia [11].
In the present study, we found that C6 cells were greatly acti-
vated by OGD insult as shown by enhanced expression of
iNOS and COX-2 along with NO overproduction. Treatment
with huperzine A reduced the overexpression of these proin-
ﬂammatory enzymes, decreased the overproduction of NO
and in turn attenuated cell damage. Our results are in accord
with previous report that huperzine A can attenuate NO-in-
duced neurotoxicity in the human neuroblastoma cell line
SK-N-SH [30]. Altogether, these ﬁndings indicate that the pro-
tective eﬀect of huperzine A against OGD-induced cell injury
may be due in part to its anti-inﬂammatory ability.
Activation of the transcription factor, NF-jB, plays a piv-
otal role in the regulation of post-ischemic inﬂammation, pos-
sibly through upregulation of proinﬂammatory genes thatcontribute to cell death in cerebral ischemia [31]. It has been
reported recently that NF-jB signaling aﬀects cell death and
COX-2 expression after OGD insult in astrocytes [26]. Since
iNOS and COX-2 genes are subject to NF-jB activation, it
was reasonable to suspect that this factor participates in
OGD-induced cell injury and to ask whether huperzine A
modulates the signaling pathways leading to NF-jB activa-
tion. We found cytotoxicity and NO overproduction in
OGD-exposed C6 cells were signiﬁcantly inhibited by PDTC,
a strong NF-jB inhibitor. These results indicate an important
role for NF-jB in ischemic cell injury. It was very interesting
that the eﬀects of 0.1 and 1 lM PDTC on cell viability were al-
most same. These results may be due to the indirect eﬀect of
PDTC on cell viability compared with its eﬀect on NO produc-
tion or the pro-apoptotic and anti-proliferative ability of
PDTC, which need further investigation [32]. Additional sup-
port for such a role comes from our results with the NF-jB
regulator, IjBa. Cerebral ischemia induces IjBa phosphoryla-
tion, followed by degradation and the subsequent nuclear
translocation of p65–p50 heterodimer, leading to a stimulation
of gene transcription. We found similar eﬀects in OGD-treated
C6 cells, which showed increased phosphorylation and degra-
dation of IjBa, as well as nuclear translocation of the NF-jB
subunit, p65. However, these phenomena were greatly inhib-
ited by treatment with huperzine A. Hence, it appeared that
huperzine A attenuated OGD-induced NF-jB activation
through blocking p65 nuclear translocation in an IjBa-depen-
dent manner. This outcome aroused our interest in identifying
earlier steps in the chain of events leading to cytoprotection.
In the peripheral nervous system, a non-neuronal cholinergic
system is strongly expressed within diﬀerent components of the
immune system and appears to be involved in the regulation of
host defense mechanisms and inﬂammation. Recent study
suggests that vagus nerve acts as an endogenous ‘‘cholinergic
anti-inﬂammatory pathway’’ that downregulates systemic
inﬂammatory response through a7 nAChR on blood-borne
macrophages [33]. The ‘‘cholinergic anti-inﬂammatory path-
way’’ is a mechanism for neural inhibition of inﬂammation
and interfaces the brain with the immune system [34,35]. An
endogenous ‘‘cholinergic anti-inﬂammatory pathway’’ in the
brain has been shown to regulate microglial activation through
a7 nAChR [36]. Acting at the same receptor, nicotinic agonists
prevent activation of NF-jB and inhibit secretion of inﬂam-
mation-related factors in experimental sepsis [37]. Some AChE
inhibitors have been shown to have anti-inﬂammatory eﬀects,
concomitantly with inhibiting AChE activity [14,15]. These
ﬁndings demonstrate that cholinergic enhancement produces
anti-inﬂammatory eﬀects and suggest a novel therapeutic
mechanism for AChE inhibitors [16]. Huperzine A, as a cholin-
esterase inhibitor, might exert similar therapeutic eﬀects.
Previous studies showed that AChE activity decreased sig-
niﬁcantly in ischemic brain [38–40]. We found the similar re-
sults in vitro. Decreased AChE activity in OGD-treated cells
might reﬂect persistent impairment of protein synthesis or a
kind of self-protection against ischemic insult. Since huperzine
A is an AChE inhibitor, it is reasonable to ﬁnd AChE activity
of OGD cells decreased further after huperzine A treatment,
which was consistent with our in vivo results [38].
Our previous study indicated that enhanced cholinergic
function was involved in the ischemic protection conferred
by huperzine A [38]. In C6 cells subjected to OGD insult, we
found that huperzine A, in a dose shown to inhibit AChE,
Fig. 3. Eﬀects of huperzine A on phospho-IjBa and IjBa levels and nuclear translocation of p65 subunit of NF-jB in C6 cells. (A) phospho-IjBa
and IjBa protein levels were evaluated by Western blot analysis. (B) Quantitative summary of results in A. (C) Nuclear translocation of p65. (a)
control group; (b) OGD group; (c) OGD group treated with 1 lM huperzine A; (d) control group treated with 1 lM huperzine A without OGD
insult. (Left panel) p65 was detected by a Cy3-labelled immunostaining (red); middle panel: nuclei were stained by DAPI (blue); (right panel)
combined images. Data were means ± S.E.M. expressed as percentage of control value, which is set to 100%. At least three independent experiments
were carried out. *P < 0.05, **P < 0.01 versus control; ##P < 0.01 versus OGD group. Scale bar = 10lm.
Fig. 4. Eﬀects of huperzine A on AChE activities in C6 cells.
Expression of AChE in C6 cells was detected by RT-PCR (A) and
Western blot analysis (B) with PC12 cells as positive controls. (C)
AChE activity. Data are means ± S.E.M. expressed as percentage of
control value, which is set to 100%. The template concentrations and
total proteins were not normalized in this case. At least three
independent experiments were carried out in triplicate. **P< 0.01
versus control; ##P < 0.01 versus OGD group.
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proinﬂammatory enzymes as well as the overproduction of
NO. The eﬀects of huperzine A on NO overproduction were
signiﬁcantly reversed by mecamylamine and a-bungarotoxin,
a non-selective nicotinic antagonist and a selective a7 nAChR
antagonist, respectively. Therefore, we suggest that the anti-
inﬂammatory eﬀects of huperzine A involve nAChR, especially
a7 subtype. Cultured mammalian glial cells and human glioma
cell line U373 could synthesize ACh [41]. We demonstrated C6
cells also synthesized ACh. Our results suggest that one under-
lying mechanism is that huperzine A inhibits AChE activityand increases the concentration of extracellular ACh, render-
ing it available for interaction with a7 nAChR, i.e. the ‘‘cholin-
ergic anti-inﬂammatory pathway’’. Another possible
therapeutic mechanism is the direct eﬀect on nAChR as shown
by our previous study about the displacement eﬀect of huper-
zine A for cholinergic ligands [42]. However, mecamylamine
and a-bungarotoxin reversed the eﬀects of huperzine A on cell
viability to a modest degree. Hence, protective eﬀects of huper-
zine A were mediated, in part, by the cholinergic pathway and
other potential non-cholinergic mechanisms are also involved.
Oxidative stress plays a pivotal role in the pathogenesis of
acute ischemic stroke, while reactive oxygen species (ROS)
can activate diverse downstream signaling pathways to regu-
late expression of genes encoding a variety of proinﬂammatory
proteins [43]. Huperzine A has been found to attenuate ROS
accumulation and protect cells against oxidative stress [9].
Therefore, besides cholinergic function, anti-oxidative ability
might also play a role in the protective eﬀects of huperzine A
on OGD injury, which need further investigation.
In conclusion, the present study demonstrate that OGD in-
sult in C6 cells activated NF-jB through enhancing phosphor-
ylation and degradation of IjBa and nuclear translocation of
NF-jB, which in turn promoted expression of the inﬂamma-
tion-related enzymes iNOS and COX-2, increased the produc-
tion of NO and ﬁnally led to cell injury. Treatment with
huperzine A was able to inhibit the phosphorylation and deg-
radation of IjBa, prevent NF-jB nuclear translocation, atten-
uate iNOS, COX-2 and NO overproduction, and promote
increased cell survival. Our results indicate that such anti-
inﬂammatory actions might contribute to the protective eﬀects
of huperzine A against OGD-induced injury in C6 cells. Since
C6 cells could synthesize ACh, these eﬀects of huperzine A
Fig. 5. Eﬀects of huperzine A on cell viability and NO production in C6 cells in the presence of mecamylamine (A, B) or a-bungarotoxin (E, F).
Expression of a7 nAChR in C6 cells was detected by RT-PCR, Western blot (C) and immunostaining assay (D). D, C6 cells were pre-incubated in the
absence (a) or presence of nicotine (b) and then incubated with FITC-labelled-a-bungarotoxin. Data were means ± S.E.M. expressed as percentage of
control value, which is set to 100%. The template concentrations and total proteins were not normalized in this case. At least three independent
experiments were carried out in triplicate. *P < 0.05, **P < 0.01. Scale bar = 10lm.
Z.F. Wang, X.C. Tang / FEBS Letters 581 (2007) 596–602 601might be due in part to the a7 nAChR-mediated ‘‘cholinergic
anti-inﬂammatory pathway’’.
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